Works Cited
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.
1. Hall JE, Hall ME. Guyton and Hall Textbook of Medical Physiology. 15th ed. Philadelphia, PA: Elsevier; 2025.
5. Mitchell R, Kumar V, Abbas AK, Aster JC. Pocket Companion to Robbins and Cotran Pathologic Basis of Disease. 10th ed. Philadelphia, PA: Elsevier; 2023.
6. Avram M, Kiahr S. Renal Disease Progression and Management: Role of Vasoactive Agents, Cytokines, Lipids, and Nutrition. Philadelphia, PA: Elsevier Health Sciences; 1996.
7. Kellerman RD, Heidelbaugh JJ, Lee EM. Conn's Current Therapy 2026. Philadelphia, PA: Saunders; 2026.
8. Xin JZ, Laszidk ZG, Nadasdy T, D'Agati VD. Silva's Diagnostic Renal Pathology. 2nd ed. Cambridge: Cambridge University Press; 2018.
10. Nowak T. Pathophysiology: Concepts and Applications for Health Care Professionals. 2nd ed. Boston, MA: McGraw-Hill; 1999.
11. Rennke H, Denton M, Magee C. Renal Disease: Prevention and Treatment. New York, NY: CRC Press; 1998.
12. Johnson G. On the Diseases of the Kidney, Their Pathology, Diagnosis, and Treatment. London: J.W. Parker and Son; 1852.
13. Lee D, Lee S, Choe H. Community-acquired urinary tract infection by Escherichia coli in the era of antibiotic resistance. Biomed Res Int. 2018;2018:7656752.
14. Clark WB. The Diagnosis and Treatment of Diseases of the Kidney Amenable to Direct Surgical Interference. London: Lewis Publishing; 1886.
15. Wilcox CS. Therapy in Nephrology and Hypertension: A Companion to Brenner and Rector's The Kidney. 3rd ed. Philadelphia, PA: Saunders/Elsevier; 2008.
16. Moorthy V. Pathophysiology of Kidney Disease and Hypertension. Philadelphia, PA: Elsevier Health Sciences; 2009.
17. Brenner BM, Coe FL, Rector FC. Renal Physiology in Health and Disease. Philadelphia, PA: Elsevier Health Sciences; 1987.
18. Gonick HC, Buckalew VM. Renal Tubular Disorders: Pathophysiology, Diagnosis and Management. New York, NY: Marcel Dekker; 1985.
19. Schoener B, Borger J. Erythropoietin-stimulating agents. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2023.
22. Rogers JL. Pathophysiology: The Biologic Basis for Disease in Adults and Children. 9th ed. St. Louis, MO: Elsevier Health Sciences; 2022.
24. Humes HD. Pathophysiology of Electrolyte and Renal Disorders. New York, NY: Churchill Livingstone; 1986.
25. Cascella M, Vaqar S. Hypermagnesemia. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2023.
26. Ajib F, Childress J. Magnesium toxicity. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2022.
27. Tisher CC, Brenner BM. Renal Pathology with Clinical and Functional Correlations. 2nd ed. Philadelphia, PA: Lippincott, Williams, and Wilkins; 1994.
28. Price SA. Pathophysiology: Clinical Concepts of Disease Processes. 7th ed. St. Louis, MO: Mosby; 2014.
29. Kato S, Chmielewski M, Honda H, et al. Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol. 2008;3(5): 1526-1533.
31. Brashers VL. Clinical Applications of Pathophysiology: Assessment, Diagnostic Reasoning and Management. 3rd ed. St. Louis, MO: Mosby; 2006.
32. Avin KG, Moorthi RN. Bone is not alone: the effects of skeletal muscle dysfunction in chronic kidney disease. Curr Osteoporos Rep. 2015;13(3):173-179.
33. Troutman AD, Arroyo E, Lim K, Moorthi RN, Avin KG. Skeletal Muscle Complications in Chronic Kidney Disease. Curr Osteoporos Rep. 2022;20(6):410-421.
34. Pagonas N, Vautz W, Seifert L, et al. Volatile organic compounds in uremia. PLoS ONE. 2012;7(9):e46258.
35. Black J, Hawks JH, Keene AM. Medical-Surgical Nursing: Clinical Management for Continuity of Care. 8th ed. Philadelphia, PA: W.B Saunders, 2008.
36. Gubrud P, Carno M-A, Bauldoff G. LeMone and Burke's Medical-Surgical Nursing: Clinical Reasoning in Patient Care. 7th ed. Upper Saddle River, NJ: Prentice Hall; 2019.
37. Ginès P. Ascites and Renal Dysfunction in Liver Disease: Pathogenesis, Diagnosis, and Treatment. Walden, MA: Blackwell; 2005.
38. Suki WN, Eknoyan G. The Kidney in Systemic Disease. New York, NY: Wiley, John and Sons, Inc.; 1981.
39. Buttaro TM, Polgar-Bailey P, Sandberg-Cook J, Dick KL, Montgomery JB. Primary Care: A Collaborative Practice. 7th ed. St. Louis, MO: Elsevier; 2024.
40. Nicholas SB, Kalantar-Zadeh K, Norris KC. Socioeconomic disparities in chronic kidney disease. Adv Chronic Kidney Dis. 2015;22(1):6-15.
41. Al-Shaikh TM, Alkaseb KS, Mudawi MME, Yassin AYA, Habeballa RS, Alzain SD. Toxicological studies on commercial hair dye brand commonly used in Saudi Arabia: histological study of the liver, kidney, heart, and testis. J Basic Appl Zoology. 2018;79:22.
42. Hallab A, Wish JB. Employment among patients on dialysis: an unfulfilled promise. Clin J Am Soc Nephrol. 2018;13(2):203-204.
43. Flynn Makic MB, Martinez-Kratz MR. Ackley and Ladwig's Nursing Diagnosis Handbook: An Evidence-Based Guide to Planning Care. 13th ed. St. Louis, MO: Elsevier; 2022.
44. Flynn Makic MB, Martinez-Kratz MR. Ackley and Ladwig's Guide to Nursing Diagnosis. 6th ed. St. Louis, MO: Elsevier; 2022.
45. Eastham J, Patel P. Phenazopyridine. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2023.
46. Arinzon Z, Shabat S, Peisakh A, Berner Y. Clinical presentation of urinary tract infection (UTI) differs with aging in women. Arch Gerontol Geriatr. 2012;55(1):145-147.
48. Zerwekh, JG, Gameau AZ. Mosby's Pharmacology Memory NoteCards: Visual, Mnemonic, and Memory Aids for Nurses. 7th ed. Philadelphia, PA: Elsevier Mosby; 2024.
49. Mount DB, Pollak MR. Molecular and Genetic Basis of Renal Disease. Philadelphia, PA: Elsevier Health Sciences; 2008.
51. Urinalysis: Reference Range, Interpretation, Collection and Panels. Available at https://emedicine.medscape.com/article/2074001-overview. Last accessed July 14, 2026.
52. Liess BD. Urine Culture. Available at https://emedicine.medscape.com/article/2093272-overview#a2. Last accessed July 14, 2026.
53. Karah N, Rafei R, Elamin W, et al. Guideline for uring culture and biochemical identification of bacterial urinary pathogens in low-resource settings. Diagnostics. 2020;10(10):832.
54. Wein AJ, Kolon TF, Peters CA, et al. Campbell-Walsh Urology 13th Edition Review. 4th ed. Philadelphia, PA: Elsevier; 2026.
55. Simon L, Sajjad H, Lopez R, et al. Bladder rupture. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2023.
56. Licina A. Acute abdominal compartment syndrome following extraperitoneal bladder perforation. Case Reports in Anesthesiology. 2017;2017:1-5.
58. Bihl GR, Petri M, Fine DM. Kidney biopsy in lupus nephritis: look before you leap. Nephrol Dial Transplant. 2006;21(7):1749-1752.
59. Blake MA, Sweeney AT. Pheochromocytoma. Available at https://emedicine.medscape.com/article/124059-overview. Last accessed July 14, 2026.
60. Albrecht TA, Battista V, Brody AA, Coats H. Oxford Textbook of Palliative Nursing. 6th ed. New York, NY: Oxford University Press; 2025.
62. Lederer E, Alsauskas ZC, Mackelaite L, Nayak V. Hyperkalemia. Available at https://emedicine.medscape.com/article/240903-overview. Last accessed July 14, 2026.
63. Longo D, Fauci AS, Kasper DL, et al. Harrison's Principles of Internal Medicine. 22nd ed. New York, NY: McGraw-Hill; 2025.
65. Wu Y, Fu YY, Zhu HD, Xu J, Walline JH. Treatment of hyperkalemic emergencies. World J Emerg Med. 2022;13(3):232-236.
66. Sterns RH, Rojas M, Bernstein P, Chennupati S. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective?J Am Soc Nephrol. 2010;21(5):733-735.
67. Tamargo J. New Drugs for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors: Hype or Hope? Available at https://www.discoverymedicine.com/Juan-Tamargo/2014/11/new-drugs-for-the-treatment-of-hyperkalemia-in-patients-treated-with-renin-angiotensin-aldosterone-system-inhibitors-hype-or-hope. Last accessed July 14, 2026.
68. LexiDrug. Available at https://online.lexi.com. Last accessed July 14, 2026.
70. Haines ST, Nolin TD, Ellingrod V, Cocohoba J, Holle LM, Posey LM. DiPiro's Pharmacotherapy: A Pathophysiologic Approach. 13th ed. New York, NY: McGraw Hill Medical; 2026.
72. Malhotra D, Tzamaloukas AH. Non-dialysis management of chronic renal failure. Med Clin North Am. 1997;81(3):749-766.
73. Skorecki K, Chertow GM, Marsden PA, Taal MW, Yu ASL. Brenner and Rector's The Kidney. 10th ed. Philadelphia, PA: Saunders; 2015.
74. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Available at https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf. Last accessed July 14, 2026.
75. NKF KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Available at https://www.kidney.org/sites/default/files/2024-08/ckd_evaluation_classification_stratification.pdf. Last accessed July 14, 2026.
76. Centers for Medicare and Medicaid Services. Medicare Coverage of Kidney Dialysis and Kidney Transplant Services. Available at https://www.medicare.gov/publications/10128-medicare-coverage-of-kidney-dialysis-kidney-transplant-services.pdf. Last accessed July 14, 2026.
77. U.S. Renal Data System. 2025 Annual Data Report. Available at https://usrds-adr.niddk.nih.gov/2025. Last accessed July 14, 2026.
78. U.S. Renal Data Reporting System. 2025 Annual Data Report. Chronic Kidney Disease. Available at https://usrds-adr.niddk.nih.gov/2025/chronic-kidney-disease. Last accessed July 14, 2026.
79. Whaley-Connell AT, Vassalotti JA, Collins AJ, Chen SC, McCullough PA. National Kidney Foundation's Kidney Early Evaluation Program (KEEP) annual data report 2011: executive summary. Am J Kidney Dis. 2012;59(3 Suppl 2):S1-S4.
80. Batuman V. Diabetic Nephropathy. Available at https://emedicine.medscape.com/article/238946-overview#a3. Last accessed July 14, 2026.
81. Gross ML, Dikow R, Ritz E. Diabetic nephropathy: recent insights into the pathophysiology and the progression of diabetic nephropathy. Kidney Int. 2005;(94):S50-S53.
82. Shumway JT, Gambert SR. Diabetic nephropathy: pathophysiology and management. Int Urol Nephrol. 2002;34(2):257-264.
83. UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854-865.
84. Jones J, Holmen J, De Graauw J, Jovanovich A, Thornton S, Chonchol M. Association of complete recovery from acute kidney injury with incident CKD stage 3 and all-cause mortality. Am J Kidney Dis. 2012;60(3):402-408.
85. Hart PD, Bakris GL. Hypertensive nephropathy: prevention and treatment recommendations. Expert Opin Pharmacother. 2010;11(16): 2675-2686.
87. Portolés J, Gorriz JL, Rubio E, et al. The development of anemia is associated to poor prognosis in NKF/KDOQI stage 3 chronic kidney disease. BMC Nephrol. 2013;14:2.
88. National Kidney Foundation. KDOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(Suppl 3):S1-S201.
89. Sarafidis PA, Blacklock R, Wood E, et al. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clin Am J Soc Nephrol. 2012;7(8):1234-1241.
90. Block GA, Ix JH, Ketteler M, et al. Phosphate homeostasis in CKD: report of a scientific symposium sponsored by the National Kidney Foundation. Am J Kidney Dis. 2013;62(3):457-473.
91. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851-860.
92. Gutierrez O. Chronic Kidney Disease Treatment and Management. Available at https://emedicine.medscape.com/article/238798-treatment. Last accessed July 14, 2026.
93. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3:1-150.
94. Perkovic V, Jardine MJ, Neal B, CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295-2306.
95. Cherney DZI, Dekkers CCJ, Barbour SJ, et al. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. Lancet Diabetes Endocrinol. 2020;8(7):582-593.
96. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436-1446.
97. The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, et al. Empagliflozin in patients with chronic kidney disease.N Engl J Med. 2023;388(2):117-127.
98. National Kidney Foundation. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis. 2002;39(Suppl 1):S1-S266.
99. American Dietetic Association. Manual of Clinical Dietetics. 6th ed. Chicago, IL: Academy of Nutrition and Dietetics; 2000.
100. London GM. Left ventricular alterations and end-stage renal disease. Nephrol Dial Transplant. 2002;17(1):S29-S36.
101. Workeneh BT, Agraharkar M, Gupta R. Acute Kidney Injury. Available at https://emedicine.medscape.com/article/243492-overview. Last accessed July 14, 2026.
102. Huether SE, McCance KL, Brashers VL. Understanding Pathophysiology. 8th ed. St. Louis, MO: Elsevier; 2025.
104. Norris TL. Porth's Pathophysiology: Concepts of Altered Health States. 11th ed. Philadelphia, PA: Wolters Kluwer; 2024.
105. Lim Y, Leslie S, O'Rourke S. Interstitial cystitis. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2023.
106. Velez R, Richmond E, Dudley-Brown S. Antibiogram, clinical practice guidelines, and treatment of urinary tract infection. J Nurse Pract. 2017;13(9):617-622.
107. Baird MS. Manual of Critical Care Nursing: Interprofessional Collaborative Management. 8th ed. St. Louis, MO: Mosby; 2022.
108. National Institute of Diabetes and Digestive and Kidney Diseases. National Kidney Disease Education Program. Available at https://www.niddk.nih.gov/health-information/community-health-outreach/information-clearinghouses/nkdep. Last accessed July 14, 2026.
110. Bruyere HJ Jr. 100 Case Studies in Pathophysiology. Philadelphia, PA: Lippincott, Williams and Wilkins: 2009.
111. Berg SM, Bittner EA, Lee J. Massachusetts General Hospital Review of Critical Care Medicine. Philadelphia, PA: Wolters, Kluwer, Lippincott, Williams & Wilkins; 2014.
112. American Cancer Society. Key Statistics About Kidney Cancer. Available at https://www.cancer.org/cancer/kidney-cancer/about/key-statistics.html. Last accessed July 14, 2026.
113. Smith S. Kidney Cancer: Causes, Symptoms, Signs, Diagnosis, Treatments, Stages of Kidney Cancer. Charleston, SC: CreateSpace; 2012.
114. American Cancer Society. Key Statistics for Bladder Cancer. Available at https://www.cancer.org/cancer/bladder-cancer/about/key-statistics.html. Last accessed July 14, 2026.
115. National Cancer Institute. Bladder Cancer Treatment (PDQ)–Health Professional Version. Available at https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq. Last accessed July 14, 2026.
116. Galvagno SM. Emergency Pathophysiology: Clinical Applications for Prehospital Care. Jackson, WY: Teton NewMedia; 2013.
117. Kosowsky JM, Resnick-Ault D. Pocket Emergency Medicine. 6th ed. Philadelphia, PA: Wolters Kluwer; 2026.
118. Bakes KM, Buchanan JA, Moreira ME, Byyny R, Pons PT. Emergency Medicine Secrets. 7th ed. Philadelphia, PA: Elsevier; 2021.
119. Fontenelle LF, Sarti TD. Kidney stones: treatment and prevention. Am Fam Physician. 2019;99(8):490-496.
120. Goldstein RS. Mechanisms of Injury in Renal Disease and Toxicity. Boca Raton, FL: CRC Press; 1994.
121. United States Renal Data System. 2025 Annual Data Report: Epidemiology of Kidney Disease in the United States. Available at https://usrds-adr.niddk.nih.gov/2025/suggested-citation. Last accessed July 14, 2026.
122. National Institute of Diabetes and Digestive and Kidney Diseases. Kidney Disease Statistics for the United States. Available at https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease. Last accessed July 14, 2026.
123. KDOQI Clinical Practice Guidelines for vascular access. Am J Kidney Dis. 2006;48(Suppl 1):S176-S247.
124. Beathard G. A practitioner's resource guide to hemodialysis arteriovenous fistulas. ESRD Network of Texas. 2003;(Suppl).
125. Lomonte C, Basile C. Preoperative assessment and planning of hemodialysis vascular access. Clin Kidney J. 2015;8(3):278-281.
126. Santoro D, Benedetto F, Mondello P, et al. Vascular access for hemodialysis: current perspectives. Int J Nephrol Renovasc Dis. 2014;7:284-294.
127. Drew DA, Lok CE. Strategies for planning the optimal dialysis access for an individual patient. Curr Opin Nephrol Hypertens. 2014;23(3):314-320.
128. Tordoir JH, Bode AS, van Loon MM. Preferred strategy for hemodialysis in access creation in elderly patients. Eur J Vasc Endovasc Surg. 2015;49(6):738-743.
129. Mansilla AV, Toombs BD, Vaughn WK, Zeledon JI. Patency and life-spans of failing hemodialysis grafts in patients undergoing repeated percutaneous de-clotting. Tex Heart Inst J. 2001;28(4):249-253.
130. Zaleski G. Declotting, maintenance, and avoiding procedural complications of native arteriovenous fistulae. Semin Intervent Radiol. 2004;21(2):83-93.
131. Centers for Medicare and Medicaid Services. Center for Clinical Standards and Quality. CMS ESRD Measures Manual for the 2026 Performance Period v11.1. Available at https://www.cms.gov/files/document/esrd-measures-manual-v11-1.pdf. Last accessed July 14, 2026.
132. Hagen SM, Lafranca JA, Ijzemans JN, Dor FJ. A systematic review and meta-analysis of the influence of peritoneal dialysis catheter type on complication rate and catheter survival. Kidney Int. 2014;85(4):920-932.
133. Lye WC, Kour NW, van der Straaten JC, Leong SO, Lee EJ. A prospective randomized comparison of the Swan neck, coiled, and straight Tenckhoff catheters in patients on CAPD. Perit Dial Int. 1996;16(Suppl 1):S333-S335.
134. Xie J, Kiryluk K, Ren H, et al. Coiled versus straight peritoneal dialysis catheters: a randomized controlled trial and meta-analysis. Am J Kidney Dis. 2011;58(6):946-955.
135. Strohmaier S, Wallisch C, Kammer M, et al. Survival benefit of first single-organ deceased donor kidney transplantation compared with long-term dialysis across ages in transplant-eligible patients with kidney failure. JAMA Network Open. 2022;5(10):e2234971.
136. Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med. 2010;363(21):2004-2014.
137. UNOS. UNOS and the Organ Procurement and Transplantation Network. Available at https://unos.org/about/who-we-serve/unos-and-the-organ-procurement-and-transplantation-network-optn. Last accessed July 14, 2026.
138. Organ Procurement and Transplantation Network. Policies: Allocation of Kidneys. Available at https://www.hrsa.gov/sites/default/files/hrsa/optn/optn_policies.pdf. Last accessed July 14, 2026.
139. Organ Procurement and Transplantation Network. Kidney Allocation System. Available at https://www.hrsa.gov/optn/professionals/resources/kidney-pancreas/kidney-allocation-system. Last accessed July 14, 2026.
140. Penn Today. Too Many Donor Kidneys Are Discarded in U.S. Before Transplantation. Available at https://penntoday.upenn.edu/news/too-many-donor-kidneys-are-discarded-us-transplantation. Last accessed July 14, 2026.
141. Tapiawala SN, Tinckam KJ, Cardella CJ, et al. Delayed graft function and the risk for death with a functioning graft. J Am Soc Nephrol. 2010;21(1):153-161.
142. Curtis JR. Palliative and end-of-life care for patients with severe COPD. Eur Respir J. 2008;32(3):796-803.
143. Renal Physicians Association. Shared Decision-Making in the Appropriate Initiation and Withdrawal from Dialysis. Clinical Practice Guideline. 2nd ed. Rockville, MD: Renal Physicians Association; 2010.
144. Larson AM, Curtis JR. Integrating palliative care for liver transplant candidates: "too well for transplant, too sick for life." JAMA. 2006;295(108):2168-2176.
145. U.S. Centers for Medicare and Medicaid Services. Hospice Determining Terminal Status. Available at https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=34538. Last accessed July 14, 2026.
146. Clayton JM, Hancock KM, Butow PN, et al. Clinical practice guidelines for communicating prognosis and end-of-life issues with adults in the advanced stages of a life-limiting illness, and their caregivers. Med J Aust. 2007;188(12 Suppl):S77, S79, S83-S108.
147. Buckman R. Communication skills in palliative care: a practical guide. Neurol Clin. 2001;19(4):989-1004.
148. Finlay E, Casarett D. Making difficult decisions easier: using prognosis to facilitate transitions to hospice. Ca Cancer J Clin. 2009;59:250-263.
149. Stapleton R, Curtis JR. End-of-life considerations in older patients who have lung disease. Clin Chest Med. 2007;28(4):801-811.
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.